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Abstract
Objective Immunosuppressant therapy plays a pivotal

role in transplant success and longevity. Tacrolimus,
a primary immunosuppressive agent, is well known
to exhibit significant pharmacological interpatient and
intrapatient variability. This variability necessitates the
collection of serial trough concentrations to ensure that
the drug remains within therapeutic range. The objective
of this study was to build a population pharmacokinetic
(PK) model and use it to determine the minimum number
of trough samples needed to guide the prediction of an
Received 31 May 2017
individual’s future concentrations.
Revised 4 August 2017
Design, setting and patients Retrospective data
Accepted 17 August 2017
from 48 children who received tacrolimus as inpatients
at Primary Children’s Hospital in Salt Lake City, Utah were
included in the study. Data were collected within the first
6 weeks after heart transplant.
Outcome measures Data analysis used population
PK modelling techniques in NONMEM. Predictive ability of
the model was determined using median prediction error
(MPE, a measure of bias) and median absolute prediction
error (MAPE, a measure of accuracy). Of the 48 children in
the study, 30 were used in the model building dataset, and
18 in the model validation dataset.
Results Concentrations ranged between 1.5 and
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elimination rate) as covariates. Our analysis demonstrated
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Conclusions The use of PK in dose guidance has the
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Introduction
Heart transplantation is an accepted therapeutic option for children with congenital

What is already known on this topic?
►► Tacrolimus is a primary immunosuppressant agent

in preventing graft rejection in children receiving
heart transplant.
►► Tacrolimus suffers from substantial interpatient and
intrapatient pharmacological variability.

What this study hopes to add?
►► This study identifies age, creatinine clearance and

fluconazole use as patient-specific factors which
impact tacrolimus pharmacokinetics.
►► The pharmacokinetic model demonstrates that
as few as three concentrations can successfully
guide the model to predict an individual’s future
concentrations.

heart disease and cardiomyopathy. More than
400 heart transplants are performed annually
in children across the USA with improving
outcomes in recent decades, though mortality
from rejection, infection and coronary vasculopathy remains significant.1 2 Transplant
survival in excess of 20 years following heart
transplantation has been observed, with more
than 70% of transplants expected to achieve
greater than 5-year survival.2 3 Much of this
success can be attributed to the use of immunosuppressive therapy to prevent the rejection of the transplanted cardiac tissue.
The calcineurin inhibitors tacrolimus and
ciclosporin play a vital role in immunosuppressive therapy. Currently, tacrolimus is
preferred in comparison to ciclosporin, owing
to its improved safety profile, especially with
regard to hypertension and dyslipidaemia.4
However, tacrolimus suffers from extensive
interpatient and intrapatient pharmacokinetic (PK) variability, which necessitates
frequent drug monitoring to guide dosing
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strategies. PK of tacrolimus in children has primarily
been studied in those patients receiving liver or kidney
transplants.5–13 There are few descriptions of tacrolimus
PK in heart transplant recipients, especially in children,
and a population PK model has yet to be described for
the paediatric population.
The current study has two objectives. First, we aimed to
develop a population PK model of tacrolimus in paediatric
heart transplant recipients. In addition to describing PK
of tacrolimus in the paediatric heart transplant population, the population PK model can assess the sources and
extent of variability associated with tacrolimus concentrations. Second, the number of tacrolimus concentrations
needed for the model to accurately predict an individual’s future concentrations was assessed. This analysis was
used to determine if the model could potentially reduce
the drug monitoring burden in children receiving heart
transplants.

Methods
Data collection
Study approval was granted by the University of Utah,
Intermountain Healthcare and Primary Children’s
Hospital Institutional Review Board. Data for this study,
including event times, dose amount, tacrolimus concentrations and demographics, were collected retrospectively from the Intermountain Healthcare Enterprise
Data Warehouse. The study included children receiving
tacrolimus during an inpatient stay at the Primary Children’s Hospital in Salt Lake City, Utah within the first
6 weeks following heart transplant between the years
of 2007 to 2015. Furthermore, children meeting these
criteria must have had at least one dose of tacrolimus
and one tacrolimus concentration to be incorporated
into the study. Data collected between 2007 and 2013
were used for model building, whereas 2014 and 2015
data were used for model validation. Clinical dosing
information was verified by scanning a bar code on the
patient’s bracelet immediately prior to tacrolimus administration. Tacrolimus was typically administered two times
per day, either orally or enterally through a nasogastric or
nasojejunal tube. In addition to tacrolimus, all patients
received mycophenolate as part of their immunosuppressive regimen, and milrinone was used to provide
cardiac support post-transplant. Concentrations were
determined from whole blood using a validated liquid
chromatography–tandem mass spectrometry (LC–MS/
MS) method at ARUP Laboratories. The assay was linear
between 1 and 40 ng/mL. Sample times were determined
relative to the first dose of tacrolimus.
PK modelling
PK modelling used NONMEM software (V.7.3; ICON
Development Solutions) interfaced with PDx-Pop (V.5.0).
The first-order conditional estimation with interaction
method was used throughout model building and evaluation. Model selection was based on parsimony, objective
2

function value (OFV) and visual diagnostic plots. Models
were parameterised on the elimination rate constant (ke)
and volume (Vd), along with the oral absorption rate
(ka) (TRANS1). One (ADVAN2) and two (ADVAN4)
compartment structural models were evaluated, along
with additive, proportional and combined (additive and
proportional) error models, to determine the best base
model for the data.
After the base model was established, covariates were
tested in the model using a stepwise forward inclusion (p<0.05)–backward exclusion (p<0.01) regression method. Covariates were added to the model in a
stepwise fashion and allowed to remain in the model if
covariate inclusion decreased the OFV by at least 3.84
(p<0.05, χ2 df=1), and its exclusion increased the OFV
by at least 6.63 (p<0.01, χ2 df=1). Categorical covariates,
including sex, administration type (oral or via feeding
tube), diet (ad libitum or prescribed diet) and use of
comedications known to inhibit or induce tacrolimus
metabolism (fluconazole being one example), were
tested by fitting model parameters to the following
equation.
∗ =θ
γ(0 or 1)
θpop

pop ∗ ∆

Where θ*pop is the covariate adjusted parameter estimate, θpop is the population parameter estimate, Δ is the
parameter estimate change for those with a covariate
value of 1 and γ refers to the value of the covariate, either
0 or 1. Postoperative day (POD) was tested in the model
on ke using an Emax/EC50 model, with and without a Hill
coefficient.
ke =

kγe, max ∗POD

kγe,50 +PODγ

Other continuous covariates, such as weight, age, body
mass index and creatinine clearance (calculated using
the bedside Schwartz equation), were population median-normalised and incorporated into the model using
the following equation:
)γ
(
COVi
∗ = θ ∗

θpop
m
COVmedian

In this equation, θ*pop is the covariate adjusted parameter estimate, θm is the parameter estimate for an individual with the median value of the covariate, COVi is
the individual covariate value, COVmedian is the population median covariate and γ refers to the exponent.
Missing data were carried forward or backwards for up
to 48 hours, as appropriate, beyond which, population
median values were imputed.
Model validation included a prediction corrected
visual predictive check and bootstrapping accomplished
using PsN 4.4.0 (psn.sourceforge.net) and Pirana 2.9.2
(http://
pirana-
software.
com), both using 1000 simulated datasets based on the data collected between 2007
and 2013. An additional model validation step compared
data observed in the validation dataset (data collected in
2014 and 2015) to data simulated from the population in
that dataset. Data were compared using median prediction error (MPE, a measure of bias) and median absolute
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prediction error (MAPE, a measure of accuracy), as
shown in the following equations:
PE =
APE =

Cpred −Cobs
Cobs 
|Cpred −Cobs |

Cobs

Predicting tacrolimus concentrations
The described population PK model structure was used
to investigate the number of samples required to predict
an individual’s future tacrolimus concentrations. The
first step in this analysis was to manipulate the dataset
such that patient-specific post hoc parameter estimates
could be determined using only the first observed
concentration from each patient. This was accomplished
by changing all but each patient’s first observed concentration to be a missing dependent variable (ie, DV=−1)
within the dataset used for this analysis. Notably, the first
observed concentration represents a trough concentration following the first tacrolimus dose for a majority of
patients. Next, an event identification (EVID) column
was added to the dataset. For each row (corresponding
to a time at which there was a study event, either a
dose or concentration), the EVID column value was set
to 0 for the concentrations being used to determine
the patient-specific post hoc parameter estimates (ie,
MDV=0), 1 for all dosing events and 2 when the concentration had been set to missing (ie, MDV=1). For all
rows where EVID=2, NONMEM will generate an individual predicted concentration based on the patient’s
post hoc parameter estimate. This manipulated dataset
was then analysed in NONMEM, and the output was used
to compare predicted individual concentrations to the
actual observed concentrations using MPE and MAPE.
For the average patient with 13 samples collected over the
course of the study, the comparison between predicted
and observed concentrations would use the final 12
samples (as the first sample had been used to generate
the individual parameter estimates). This analysis was
then repeated by sequentially including each patient’s
next chronological concentration in the model, up to the
first five observed concentrations for each patient. These
results were used to determine the minimum number
of concentrations needed to accurately and precisely
predict future concentrations. An MPE and MAPE of less
than 30% was targeted to define the minimum number
of samples that were necessary to accurately and precisely
predict future tacrolimus concentrations.
Results
Study population
Data for model building were obtained from 30 paediatric heart transplant recipients, whereas the model
validation dataset included 18 children. Individuals in
the model building dataset were primarily men (n=19),
Caucasian (n=28), with median (range) age of 5.7 (0.1 to
17.7) years and weight of 28.9 (7.0 to 77.2) kg. The validation dataset was evenly split by sex (nine men and

nine women), largely Caucasian (n=15), with median
(range) age of 2.0 (0.3 to 18.4) years and weight of 11.2
(4.9 to 63.0). Median (range) doses were 0.09 (0.02 to
0.49) and 0.17 (0.03 to 0.69) mg/kg/day for the model
building and validation datasets, respectively. A total of
395 samples (on average 13 per patient) were collected
from patients in the model building cohort, whereas 330
samples (on average 18 per patient) were collected from
patients in the model validation cohort. Approximately
40% of trough concentrations were within the target
range of 12 to 16 µg/L for both datasets. Additional
demographic information for the studied population is
summarised in table 1.
Population PK model
A one-compartment structural model with additive error
was selected as the base model. A one compartment
structural model was selected owing to the minimal
improvement in model fit when a peripheral compartment was added to the model. The additive error model
was chosen based on model stability. Base model parameter estimates are shown in table 2. The ka parameter was
estimated during base model construction. However, estimation of this parameter resulted in some model instability, likely because limited absorption phase data were
available for model building. Therefore, the ka estimated
from the base model (ka=3.43/hour) was fixed to that
value prior to covariate modelling.
During the forward inclusion step of stepwise covariate
modelling, creatinine clearance and fluconazole use were
found to be significantly associated with ke, whereas age
was associated with Vd (p<0.0001). Additionally, postoperative day was found to be significantly associated with ke;
however, the inclusion of this covariate caused significant
model instability and prevented proper model convergence. As a result, this covariate was removed from the
model and not included in further analyses. Including
creatinine clearance in the model resulted in the greatest
improvement in model fit, followed by the impact of age
and, finally, fluconazole use. Tacrolimus elimination was
reduced by 34% in those patients coadministered fluconazole compared with those children who did not receive
fluconazole. All of these relationships were retained
during the backwards exclusion modelling step. Final
parameter estimates were as follows, where fluconazole
use was indicated with FLUC=1 (table 2).
)0.85
(
) (

ke = 0.0408 ∗ 0.657FLUC ∗ CRCL
122.4
(
( ) )0.775
AGE yrs

Vd = 233 ∗
5.7
Model diagnostic plots demonstrated adequate model
fit (figure 1A–D). Eta-shrinkage was 16% on ke and 14%
on Vd. Visual predictive check (figure 2) and bootstrapping (table 2) supported the model. Additionally, the
constructed model was validated using data collected in
2014–2015 that were not available when the model was
initially constructed. The analysis supported the model
as having minimal bias (MPE (95% CI): −3.8% (−7.6 to
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the number of concentrations used to guide the model.
MAPE decreased from 44.0% when one concentration was used to 24.1% when three concentrations
were used (table 3). The reduction in MAPE (therefore, the improvement in accuracy) from three to five
(MAPE=21.4%) concentrations was minimal. Given the
minimal improvement in accuracy and the added time
burden of collecting those additional samples, three
concentrations were selected as the minimal number
required to successfully predict subsequent tacrolimus
concentrations for an individual.

Table 1 Demographic characteristics of the study
population
Model building
dataset

Model validation
dataset

January 2007–
December 2013
30

January 2014–
December 2015
18

 Male

19

9

 Female

11

9

 Caucasian

28

15

 African-American

1

1

 Other

1

2

 Yes

15

16

 No

15

2

5.7 (0.1 to 17.7)

2.0 (0.3 to 18.4)

28.9 (7.0 to 77.2)

11.2 (4.9 to 63.0)

122.4 (15.6 to
442.2)

104.7 (8.5 to
224.9)

 Congenital heart
disease

14

8

 Cardiomyopathy

16

9

 Arrhythmia

0

1

Study period
Subjects
Sex

Race

Fluconazole use

Age (year)
 Median (range)
Weight (kg)
 Median (range)
Creatinine clearance
(mL/min/1.73 m2)
Median (range)
Transplant
indications

Dose (mg/kg/day)
 Median (range)

0.09 (0.02 to 0.49) 0.17 (0.03 to 0.69)

Concentration (µg/L)
 Median (range)

12.7 (1.5 to 32.7)

13.4 (2.5 to 37.7)

 <12 µg/L

41%

36%

 12 to 16 µg/L
 >16 µg/L

39%
20%

40%
24%

−0.27)) and good accuracy (MAPE (95% CI): 19.4%
(16.9 to 22.6)) when predicting concentrations from the
validation dataset. Combined, the model diagnostics and
validation analysis support the fit of the described model.
Predicting tacrolimus concentrations
The model structure (including covariates) described
above was used to predict subsequent tacrolimus concentrations when between one and five concentrations were
used to determine individual parameter estimates. MPE
ranged between −2.1% and 1.9% (table 3), suggesting
minimal bias in predicted concentrations, regardless of
4

Discussion
Tacrolimus provides great value to transplant success
as the mainstay of transplant immunosuppression, but
extensive interpatient and intrapatient variability complicates its clinical use. The population PK model identifies
some of the causes of tacrolimus variability in paediatric
heart transplant recipients, namely patient age, renal
function and comedications that impact tacrolimus
metabolism, such as fluconazole. Furthermore, we show
that the constructed model can be used to successfully
predict future tacrolimus concentrations when guided
by as few as three concentrations in an individual, which
may help reduce the drug monitoring burden in this
patient population.
The described population PK model was used to estimate mean population parameters describing tacrolimus
disposition. For a child of median age and creatinine
clearance, who did not receive fluconazole, mean elimination rate and volume were 0.0408/hour and 233 L,
respectively. Literature has reported a wide range of
model structures and parameter estimates for tacrolimus. One-compartment and two-compartment models
with and without lag times have been reported for paediatric kidney and liver transplant recipients.5 6 10 13 The
differences in model structure inhibit the direct comparison of previously determined parameter estimates;
however, previous reports describe elimination rates
between 0.0271 and 0.102/hour (half lives between 6.8
and 25.6 hours), similar to the value observed in this
study.5 6 10 11 The similarity between the elimination
rate parameter in our model compared with the rates
that have previously been reported supports the appropriateness of the constructed model. Furthermore, the
similarity in parameter estimates between our model
and those models which have been previously published
supports the potential for applying this model to help
guide tacrolimus dosing at other institutions and across
multiple transplant organs.
We determined that concomitant use of fluconazole
and creatinine clearance significantly impacted the
elimination of tacrolimus, whereas age was associated
with volume. The rationale behind the impact of creatinine clearance on tacrolimus elimination is unclear,
as tacrolimus is predominately liver metabolised.14
However, serum creatinine levels have previously been
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Table 2 Population pharmacokinetic parameter estimates
Base model

Final model

Bootstrap
(977/1000 successful)

Parameters
 Elimination rate (1/hour)

Population mean (%RSE)
0.0317 (13%)

0.0408 (15%)

Median (2.5 to 97.5 percentile)
0.0411 (0.0318 to 0.0558)

 Volume (L)

216 (22%)

233 (17%)

228 (167 to 312)

 Absorption rate (1/hour)

3.43 (fixed)

3.43 (fixed)

3.43 (fixed)

 Volume: age exponent

–

0.775 (13%)

0.780 (0.601 to 1.01)

 Elimination rate: creatinine
clearance exponent

–

0.850 (24%)

0.842 (0.470 to 1.25)

 Fluconazole elimination rate (1/
hour)

–

0.0268 (5%)

0.0267 (0.0234 to 0.0321)

Between-subject variability
 
ωke2

0.219 (51%)

0.262 (40%)

0.256 (0.0858 to 0.590)

 
ωV2

0.991 (27%)

0.329 (35%)

0.291 (0.0637 to 0.518)

Residual error
 Additive (µg/L)

SD (%RSE)
4.24 (14%)

3.69 (13%)

3.65 (3.16 to 4.14)

associated with tacrolimus clearance in other population
PK studies,15–17 underscoring the need for future research
to understand the physiological relevance of this association. It has previously been hypothesised that high serum
creatinine may be a surrogate indicator of a subclinical
hepatic injury that causes altered renal blood flow15 or
some other alteration in drug metabolism related to the
hepatorenal syndrome.16 It is also possible that the impact
of creatinine clearance in our model could be driven

by changes in bioavailability caused by renal dysfunction. Notably, a study in rats found increased tacrolimus
bioavailability in those animals with cisplatin-induced
renal failure versus animals with normal renal function.18
More work is needed to clarify the physiological rationale behind the relationship between creatinine clearance and tacrolimus elimination and to determine the
utility of including this covariate when predicting dosing
requirements in patients.

Figure 1 Diagnostic plots for the final
model, including (A) observed versus
population predicted concentrations,
(B) observed versus individual predicted
concentrations, (C) conditional
weighted residuals versus time after
dose and (D) conditional weighted
residuals versus population predicted
concentration. CWRES, conditional
weighted residual; TAD, time after dose.
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Figure 2 Prediction corrected visual predictive check
showing observed data concentrations (blue circles) and
percentiles (red dashed lines: fifth and 95th percentile, red
solid line: 50th percentile) versus time. Shaded area reflects
the simulated concentrations and the respective 95% CI at
the fifth and 95th percentile (black dashed line, blue shading)
and 50th percentile (black solid line, pink shading).

The interaction between fluconazole and tacrolimus has
previously been noted in liver and kidney transplant recipients. Fluconazole use was associated with a 34% decrease in
tacrolimus elimination in our population, which is similar
to a previous report of a 35% reduction in clearance in an
adult liver transplant population.19 Another report suggests
the need for a 40% decrease in tacrolimus dosing to maintain the attainment of target tacrolimus concentrations in
adult renal transplant patients who were coadministered
fluconazole.20 Interestingly, a study in paediatric liver transplant recipients proposed that fluconazole reduces tacrolimus elimination and that the magnitude of the reduction
was dependent on the donor’s CYP3A5 genotype.12 Specifically, the authors of this study found that fluconazole
reduced the hepatic clearance of tacrolimus by 30% when
the donor liver expressed CYP3A5 (ie, *1/*1 or *1/*3), and
60% when the donor liver did not express this genotype
Table 3 Median prediction error (MPE, measure of bias)
and median absolute prediction error (MAPE, measure of
accuracy) when between one and five concentrations were
used to guide predicted concentrations
Concentrations MPE (95% CI)

MAPE (95% CI)

1
2

−0.40 (−8.3 to 0.00)
−2.1 (−6.7 to 0.80)

44.0 (39.6 to 50.0)
31.3 (27.4 to 36.5)

3

0.10 (−2.9 to 3.7)

24.1 (19.7 to 27.7)

4
5

1.9 (−2.7 to 5.7)
1.8 (−1.4 to 6.3)

21.7 (19.2 to 24.2)
21.4 (17.5 to 23.7)

6

(ie, *3/*3). Unfortunately, our data did not allow the analysis of the impact of CYP3A5 expression on the interaction
between fluconazole and tacrolimus; therefore, future work
considering the impact of this genotype when the donated
organ is not the organ responsible for drug metabolism (ie,
in heart transplantation) is required.
When guided by as few as three concentrations, the
constructed population PK model successfully predicted
an individual’s future tacrolimus concentrations with
negligible bias and acceptable accuracy. The data used in
our study represents drug monitoring every 12 hours (ie,
trough concentrations) as is customary at our institution
immediately after transplant surgery. While guiding the
predictions with more than three concentrations improved
the accuracy of the predictions, the improvements were
small. As an example, to improve prediction accuracy by
2.4% (from an MAPE of 24.1% (3 concentrations) to 21.7%
(4 concentrations)) would require an additional 12 hours
of unoptimised care given the current standard practice.
The minimal increase in accuracy was deemed to be insufficient compared with risk of providing unoptimised care.
While the use of three concentrations to guide tacrolimus
dosing must be validated clinically, these results exemplify
the potential for and great benefits of providing care that is
optimised and directed for an individual patient.
Previous literature has described the use of population
PK models for Bayesian forecasting of tacrolimus concentrations, similar to our analysis. While most of these studies
were conducted in adult kidney transplant recipients,21–29
a few studied paediatric transplant recipients.9 30–32
Across all populations, MPE (bias) ranged between
−15% and 10%, whereas MAPE (accuracy) ranged from
0.8% to 40%.9 21–32 The MPE and MAPE determined in
our current study compare well with these previously
published studies. Notably, while other studies achieved
high accuracy and low bias with frequent sampling immediately after dosing, our prediction demonstrated negligible bias and acceptable accuracy despite primarily using
trough concentration data. We therefore anticipate that
refining our model with more robust concentration data
collected from a prospective clinical study may improve
the prediction accuracy generated by our model.
Our data demonstrated that ~60% of observed concentrations in our study were outside of the target therapeutic
range (12–16 µg/L). A majority of these concentrations
were below the therapeutic target, suggesting the potential for increased risk of graft rejection, with the immediate post-transplant period known to be one of the
highest risk periods.2 This finding underscores the need
for individualised tacrolimus dosing guidance to get each
patient into therapeutic range as quickly as possible.
Though it is anticipated that clinicians would suggest a
dose increase when a trough concentration <12 µg/L is
observed, this was found to be the case only 55% of the
time at our institution.33 Furthermore, the uncertainty
in prescribing the correct dose modification could be
avoided by using individualised dosing guidance based
on a population PK model.
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While our analysis offers many strengths, there are some
limitations. First, our study used retrospective clinical data
largely consisting of trough concentrations. As a result, we
did not have sufficient data to stably estimate the rate of
absorption. Additionally, the lack of non-trough data likely
explains the overpredictions in the population predicted
versus observed concentration diagnostic plots. However,
our parameter estimates agreed well with previous literature
reports, and the subsequent analyses successfully demonstrated the model’s ability to predict future concentrations.
Therefore, while additional data allowing the estimation
of the absorption rate might improve the predictive ability
of the model, the absence of that data has not significantly
impacted the current clinically driven analysis. Additionally, owing to the retrospective nature of the data collected,
we were unable to assess if more frequent sampling could
be used to improve prediction accuracy while decreasing
the time prior to optimising an individual’s dose. At the
same time, the tolerability of frequent sampling in paediatric heart transplant recipients is unknown. As a result,
we feel that our analysis describes a more realistic clinical
scenario and is therefore applicable to clinical practice.
Owing to the clinical, retrospective nature of the collected
data, we do not have CYP3A5 genotype data for the studied
patients. CYP3A5 genotype has been previously described
to impact dosing in children receiving heart transplants.34 35
A future prospective study is needed to assess the potential
for improving the model’s predictive ability when CYP3A5
genotype is incorporated. Finally, the collected data was
limited to inpatients within the first 6 weeks following transplant in order to reduce variability due to non-adherence
or misreported dose times that may occur in the outpatient
setting. More work is needed to evaluate the utility of this
approach in the outpatient setting where adherence to
prescribed dose and timing of immunosuppression may be
more variable, as well as validating this current model in a
more heterogeneous population.
In conclusion, we constructed a population PK model
that describes tacrolimus concentrations in paediatric
patients receiving heart transplant. The model demonstrated success in predicting future concentrations in
this population based on patient-specific characteristics
(including age, renal function and fluconazole, a comedication known to affect tacrolimus metabolism), though
that success needs to be replicated with a prospective trial
to demonstrate its clinical utility. If successful, this approach
could greatly benefit the clinical use of tacrolimus by
enabling patients to achieve their target therapeutic range
quickly and accurately. Maintaining a patient within target
therapeutic range is expected to positively influence the
rates of rejection and infection that directly impact graft
and patient survival. This approach also has the potential to
minimise the frequency of drug monitoring in this patient
population. Delivering optimal, PK-guided, individualised
directed care can provide significant and meaningful positive effects on the post-transplant lives of children receiving
heart transplant.
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